<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20241116011409&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20241116011409&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 16 Nov 2024 06:14:10 +0000</lastbuilddate>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39546393/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Inferences about clinical impacts based on population-level mean treatment effects may be misleading, since even small between-group differences may reflect clinically important treatment benefits for individual patients. Results of this study suggest that clinical trials should explicitly describe the distributions of KCCQ change at the patient level within treatment groups to support the clinical interpretation of their results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 15. doi: 10.1001/jamacardio.2024.4470. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a commonly used outcome in heart failure trials. While comparing means between treatment groups improves statistical power, mean treatment effects do not necessarily reflect the clinical benefit experienced by individual patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association between mean KCCQ treatment effects and the proportions of patients experiencing clinically important improvements across a range of clinical trials and heart failure etiologies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A patient-level analysis of 11 randomized clinical trials, including 9977 patients, was performed to examine the association between mean treatment effects and the KCCQ Overall Summary Score (OSS) and the absolute differences in the proportions of patients experiencing clinically important (≥5 points) and moderate to large (≥10 points) improvements. There was no target date range, and included studies were those for which patient-level data were available. Validation was performed in 7 additional trials. The data were analyzed between July 1 and September 15, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Proportion of patients experiencing an improvement of 5 or more and 10 or more points in their KCCQ score (with each domain transformed to a range of 0 to 100 points, where higher scores represent better health status).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Group mean KCCQ-OSS differences were strongly correlated with absolute differences in clinically important changes (Spearman correlations 0.76-0.92). For example, a mean KCCQ-OSS treatment effect of 2.5 points (half of a minimally important difference for an individual patient) was associated with an absolute difference of 6.0% (95% prediction interval [PI], 4.0%-8.1%) in the proportion of patients improving 5 or more points and 5.0% (95% PI, 3.1%-7.0%) in the proportion improving 10 or more points, corresponding to a number needed to treat of 17 (95% PI, 12-25) and 20 (95% PI, 14-33), respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Inferences about clinical impacts based on population-level mean treatment effects may be misleading, since even small between-group differences may reflect clinically important treatment benefits for individual patients. Results of this study suggest that clinical trials should explicitly describe the distributions of KCCQ change at the patient level within treatment groups to support the clinical interpretation of their results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39546393/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39546393</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4470>10.1001/jamacardio.2024.4470</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39546393</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mohammad Abdel Jawad</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Charles F Sherrod</dc:creator>
<dc:creator>Mirza S Khan</dc:creator>
<dc:creator>Nobuhiro Ikemura</dc:creator>
<dc:creator>Paul S Chan</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis</dc:title>
<dc:identifier>pmid:39546393</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4470</dc:identifier>
</item>
<item>
<title>Interpreting Health Status Measures in Patients With Heart Failure-What Counts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39546392/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 15. doi: 10.1001/jamacardio.2024.4610. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39546392/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39546392</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4610>10.1001/jamacardio.2024.4610</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39546392</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Interpreting Health Status Measures in Patients With Heart Failure-What Counts</dc:title>
<dc:identifier>pmid:39546392</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4610</dc:identifier>
</item>
<item>
<title>Rural-Urban Differences in Cardiovascular Mortality in the United States, 2010-2022</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 23:S0735-1097(24)09779-1. doi: 10.1016/j.jacc.2024.09.1215. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545907</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1215>10.1016/j.jacc.2024.09.1215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545907</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lucas X Marinacci</dc:creator>
<dc:creator>ZhaoNian Zheng</dc:creator>
<dc:creator>Stephen Mein</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rural-Urban Differences in Cardiovascular Mortality in the United States, 2010-2022</dc:title>
<dc:identifier>pmid:39545907</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1215</dc:identifier>
</item>
<item>
<title>Sedentary Behavior and Risk of Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 8:S0735-1097(24)10415-9. doi: 10.1016/j.jacc.2024.11.002. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545906</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.002>10.1016/j.jacc.2024.11.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545906</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Charles B Eaton</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sedentary Behavior and Risk of Cardiovascular Disease</dc:title>
<dc:identifier>pmid:39545906</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.002</dc:identifier>
</item>
<item>
<title>P2Y&lt;sub>;12&lt;/sub>; Inhibitor Pretreatment in Non-ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a national U.S. registry, we observed significant variability in the use of P2Y(12) inhibitor pretreatment among NSTE-ACS patients. Given the lack of clear advantages and the potential for prolonged hospital stays, our findings highlight the importance of efforts to improve standardization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 7:S0735-1097(24)09843-7. doi: 10.1016/j.jacc.2024.09.1227. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although high rates of P2Y<sub>12</sub> inhibitor pretreatment (defined as the administration before coronary angiography) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) have been reported, contemporary U.S. practice patterns are not well studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to investigate the temporal U.S. trends, variability, and clinical outcomes of P2Y<sub>12</sub> inhibitor pretreatment in NSTE-ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutive patients who underwent early invasive strategy for NSTE-ACS (coronary angiography ≤24 hours of arrival) in the National Cardiovascular Data Registry Chest Pain-Myocardial Infarction (MI) Registry were analyzed. A time-trend analysis was conducted on a complete cohort between January 1, 2013, and March 31, 2023. Subsequently, a more recent cohort (January 1, 2019, to March 31, 2023) with a complete set of variables was used to construct hierarchical regression models to quantify the variability in the use of pretreatment among operators and institutions. For this contemporary cohort, instrumental variable analysis, with operator preference as the instrument, was performed to compare the in-hospital outcomes between patients who received pretreatment and those who did not.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Use of P2Y<sub>12</sub> inhibitor pretreatment decreased from 24.8% in 2013Q1 to 12.4% in 2023Q1. Among the contemporary cohort of 110,148 patients (2019-2023; mean age 63.9 ± 12.5 years; 33.0% female), 17,509 (15.9%) received pretreatment. Significant variability in P2Y<sub>12</sub> inhibitor pretreatment was observed (range: 0%-100%): hierarchical regression model demonstrated that 2 similar patients would have a >;3-fold difference in the odds of pretreatment from 1 random operator or institution as compared with another (median OR: 3.74 [95% CI: 3.57-3.91] and 3.63 [95% CI: 3.51-3.74], respectively). Instrumental variable analysis demonstrated no significant differences in in-hospital all-cause death (1.5% vs 1.7%; P = 0.07), recurrent MI (0.6% vs 0.6%; P = 0.98), or major bleeding (2.7% vs 2.8%; P = 0.98) with pretreatment. However, in patients who underwent coronary artery bypass surgery, pretreatment was associated with a longer length of stay (11.2 ± 5.1 days vs 9.8 ± 5.0 days; P &lt; 0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a national U.S. registry, we observed significant variability in the use of P2Y<sub>12</sub> inhibitor pretreatment among NSTE-ACS patients. Given the lack of clear advantages and the potential for prolonged hospital stays, our findings highlight the importance of efforts to improve standardization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545905</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1227>10.1016/j.jacc.2024.09.1227</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545905</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Kevin F Kennedy</dc:creator>
<dc:creator>Jennifer A Rymer</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Frederick A Masoudi</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Shun Kohsaka</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>P2Y&lt;sub>;12&lt;/sub>; Inhibitor Pretreatment in Non-ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry</dc:title>
<dc:identifier>pmid:39545905</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1227</dc:identifier>
</item>
<item>
<title>Calcific Aortic Valve Disease: Lp(a) Takes the Heat, But Is OxPL Really Fanning the Flames?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 6:S0735-1097(24)10048-4. doi: 10.1016/j.jacc.2024.09.1240. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545904</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1240>10.1016/j.jacc.2024.09.1240</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545904</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Maxim E Annink</dc:creator>
<dc:creator>S Matthijs Boekholdt</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Calcific Aortic Valve Disease: Lp(a) Takes the Heat, But Is OxPL Really Fanning the Flames?</dc:title>
<dc:identifier>pmid:39545904</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1240</dc:identifier>
</item>
<item>
<title>Accelerometer-Measured Sedentary Behavior and Risk of Future Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545903/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Sedentary behavior is broadly associated with future adverse CV outcomes, with particularly prominent effects on HF and CV mortality, where risk inflected at approximately 10.6 h/d. Although guideline-adherent MVPA partially mitigates excess risk, optimizing sedentary behavior appears to be important even among physically active individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 11:S0735-1097(24)09920-0. doi: 10.1016/j.jacc.2024.10.065. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Beyond serving as a marker for insufficient physical activity, sedentary behavior may directly affect future cardiovascular (CV) disease risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to examine associations between accelerometer-measured sedentary behavior with risk of specific CV outcomes, including potential relations with moderate to vigorous physical activity (MVPA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among participants of the UK Biobank prospective cohort study, we fit Cox models adjusted for demographic and lifestyle factors to assess associations between accelerometer-measured daily sedentary time with incident atrial fibrillation (AF), myocardial infarction (MI), heart failure (HF), and CV mortality. We assessed the potential effect of MVPA on associations between sedentary time and CV disease by including MVPA as an adjustment variable, as well as performing subgroup analyses stratified at the guideline-recommended MVPA threshold (ie, ≥150 min/wk). We then performed compositional analyses to estimate the effects of reallocating sedentary time to other activities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 89,530 individuals (age 62 ± 8 years, 56.4% women) undergoing 1 week of accelerometry, median sedentary time was 9.4 h/d (Q1-Q3: 8.2-10.6). In multivariable models, using the second quartile (8.2-9.4 h/d) as a referent, sedentary time in the top quartile (>;10.6 h/d) was associated with greater risks of HF (HR: 1.45; 95% CI: 1.28-1.65) and CV mortality (HR: 1.62; 95% CI: 1.34-1.96), with an inflection of risk at 10.6 h/d. Higher sedentary time was also associated with greater risks of incident AF (HR: 1.11; 95% CI: 1.01-1.21) and MI (HR: 1.15; 95% CI: 1.00-1.32), with an approximately linear relation. Associations with HF and CV mortality persisted among individuals meeting guideline-recommended MVPA levels. Among individuals with >;10.6 h/d of sedentary time, reallocating sedentary behavior to other activities substantially reduced the excess CV risk conferred by sedentary behavior (eg, 30-minute decrease in sedentary time for HF: HR: 0.93; 95% CI: 0.90-0.96), even among individuals meeting guideline-recommended MVPA (HR: 0.93; 95% CI: 0.87-0.99).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sedentary behavior is broadly associated with future adverse CV outcomes, with particularly prominent effects on HF and CV mortality, where risk inflected at approximately 10.6 h/d. Although guideline-adherent MVPA partially mitigates excess risk, optimizing sedentary behavior appears to be important even among physically active individuals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545903/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545903</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.065>10.1016/j.jacc.2024.10.065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545903</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ezimamaka Ajufo</dc:creator>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>Timothy W Churchill</dc:creator>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>Krishna G Aragam</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Accelerometer-Measured Sedentary Behavior and Risk of Future Cardiovascular Disease</dc:title>
<dc:identifier>pmid:39545903</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.065</dc:identifier>
</item>
<item>
<title>Oxidized Phospholipids and Calcific Aortic Valvular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545902/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: OxPL-apoB is a predictor of the presence, incidence, and progression of AVC and established AS, particularly in the setting of elevated Lp(a) levels, and may represent a novel therapeutic target for CAVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)08460-2. doi: 10.1016/j.jacc.2024.08.070. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Oxidized phospholipids (OxPLs) are carried by apolipoprotein B-100-containing lipoproteins (OxPL-apoB) including lipoprotein(a) (Lp[a]). Both OxPL-apoB and Lp(a) have been associated with calcific aortic valve disease (CAVD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to evaluate the associations between OxPL-apoB, Lp(a) and the prevalence, incidence, and progression of CAVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: OxPL-apoB and Lp(a) were evaluated in MESA (Multi-Ethnic Study of Atherosclerosis) and a participant-level meta-analysis of 4 randomized trials of participants with established aortic stenosis (AS). In MESA, the association of OxPL-apoB and Lp(a) with aortic valve calcium (AVC) at baseline and 9.5 years was evaluated using multivariable ordinal regression models. In the meta-analysis, the association between OxPL-apoB and Lp(a) with AS progression (annualized change in peak aortic valve jet velocity) was evaluated using multivariable linear regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In MESA, both OxPL-apoB and Lp(a) were associated with prevalent AVC (OR per SD: 1.19 [95% CI: 1.07-1.32] and 1.13 [95% CI: 1.01-1.27], respectively) with a significant interaction between the two (P &lt; 0.01). Both OxPL-apoB and Lp(a) were associated with incident AVC at 9.5 years when evaluated individually (interaction P &lt; 0.01). The OxPL-apoB∗Lp(a) interaction demonstrated higher odds of prevalent and incident AVC for OxPL-apoB with increasing Lp(a) levels. In the meta-analysis, when analyzed separately, both OxPL-apoB and Lp(a) were associated with faster increase in peak aortic valve jet velocity, but when evaluated together, only OxPL-apoB remained significant (ß: 0.07; 95% CI: 0.01-0.12).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: OxPL-apoB is a predictor of the presence, incidence, and progression of AVC and established AS, particularly in the setting of elevated Lp(a) levels, and may represent a novel therapeutic target for CAVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545902/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545902</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.070>10.1016/j.jacc.2024.08.070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545902</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Harpreet S Bhatia</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Neil Craig</dc:creator>
<dc:creator>Romain Capoulade</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Patrick J Trainor</dc:creator>
<dc:creator>Seamus P Whelton</dc:creator>
<dc:creator>Rishi Rikhi</dc:creator>
<dc:creator>Karita C F Lidani</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>Michael Y Tsai</dc:creator>
<dc:creator>Michael H Criqui</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:creator>Andrew P DeFilippis</dc:creator>
<dc:creator>George Thanassoulis</dc:creator>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Oxidized Phospholipids and Calcific Aortic Valvular Disease</dc:title>
<dc:identifier>pmid:39545902</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.070</dc:identifier>
</item>
<item>
<title>What Is the Rush?: Optimizing the Timing of P2Y&lt;sub>;12&lt;/sub>; Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 13:S0735-1097(24)10300-2. doi: 10.1016/j.jacc.2024.10.099. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545901</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.099>10.1016/j.jacc.2024.10.099</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545901</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Joseph M Kim</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>What Is the Rush?: Optimizing the Timing of P2Y&lt;sub>;12&lt;/sub>; Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes</dc:title>
<dc:identifier>pmid:39545901</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.099</dc:identifier>
</item>
<item>
<title>The Association of Hospital-Cardiologist Integration With Patient Outcomes, Care Quality, and Utilization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among U.S. cardiologists, there has been a large shift from independent practice to direct employment by hospitals. We found minimal evidence that cardiologist employment by hospitals improves care quality or outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 13:S0735-1097(24)10357-9. doi: 10.1016/j.jacc.2024.10.109. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiologists are increasingly moving from independent practice to direct employment by hospitals. Hospital employment has the potential to improve care coordination and delivery, but little is known about its effect on care quality and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, we sought to assess the association between hospital employment of cardiologists and patient outcomes, care quality, and utilization among patients hospitalized with incident acute myocardial infarction (AMI) or heart failure (HF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used a sample of Medicare fee-for-service beneficiaries hospitalized with incident AMI or HF from 2008 to 2019. We identified the accountable cardiologists that cared for these patients and determined their employment status by means of tax identification numbers. We used difference-in-differences methods to compare clinical outcomes, quality measures, and utilization for patients treated by hospital-employed cardiologists after switching from independent to hospital-employed practice, to outcomes for patients treated by cardiologists who remained independent. Models were adjusted for time trends and patient, hospital, and cardiologist characteristics. Patient outcomes were in-hospital mortality, 30-day mortality, and 30-day readmission. Quality measures were receipt of: 1) a guideline-recommended test to assess cardiac function; and 2) a 30-day follow-up clinic visit. Utilization measures were length of stay and, for AMI patients, the proportion receiving coronary revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The proportion of U.S. cardiologists employed by hospitals increased from 26% in 2008 to 63% in 2019. We identified 186,052 AMI and 259,849 HF patients cared for by cardiologists who switched to hospital employment and 168,052 AMI and 245,769 HF patients cared for by independent cardiologists. Patient characteristics were similar (mean age 80.8 years; 47% men). We found no significant differences in outcomes (eg, adjusted difference in 30-day mortality 0.03% [95% CI: -0.39% to 0.45%] for AMI patients and -0.05% [95% CI: -0.37% to 0.27%] for HF patients); no differences in most quality metrics except a small increase in the proportion of HF patients with 30-day follow-up (adjusted difference: 1.04%; 95% CI: 0.46%-1.62%); and no differences in utilization between patients treated by hospital-employed cardiologists (postswitch) vs independent cardiologists.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among U.S. cardiologists, there has been a large shift from independent practice to direct employment by hospitals. We found minimal evidence that cardiologist employment by hospitals improves care quality or outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545900</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.109>10.1016/j.jacc.2024.10.109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545900</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ali Moghtaderi</dc:creator>
<dc:creator>David J Magid</dc:creator>
<dc:creator>Andy Ye Yuan</dc:creator>
<dc:creator>Bernard Black</dc:creator>
<dc:creator>Qian Eric Luo</dc:creator>
<dc:creator>Vinay Kini</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Association of Hospital-Cardiologist Integration With Patient Outcomes, Care Quality, and Utilization</dc:title>
<dc:identifier>pmid:39545900</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.109</dc:identifier>
</item>
<item>
<title>Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Internationally derived and endorsed definitions for outcome measures for a range of common cardiovascular diseases and interventions are presented. These may be used for data alignment to enable high-quality observational and randomized clinical research, audit, and quality improvement for patient benefit.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 15:ehae724. doi: 10.1093/eurheartj/ehae724. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Standardized definitions for outcome measures in randomized clinical trials and observational studies are essential for robust and valid evaluation of medical products, interventions, care, and outcomes. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) project of the European Society of Cardiology aimed to create international data standards for cardiovascular clinical study outcome measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The EuroHeart methods for data standard development were used. From a Global Cardiovascular Outcomes Consortium of 82 experts, five Working Groups were formed to identify and define key outcome measures for: cardiovascular disease (generic outcomes), acute coronary syndrome and percutaneous coronary intervention (ACS/PCI), atrial fibrillation (AF), heart failure (HF) and transcatheter aortic valve implantation (TAVI). A systematic review of the literature informed a modified Delphi method to reach consensus on a final set of variables. For each variable, the Working Group provided a definition and categorized the variable as mandatory (Level 1) or optional (Level 2) based on its clinical importance and feasibility.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Across the five domains, 24 Level 1 (generic: 5, ACS/PCI: 8, AF: 2; HF: 5, TAVI: 4) and 48 Level 2 (generic: 18, ACS-PCI: 7, AF: 6, HF: 2, TAVI: 15) outcome measures were defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Internationally derived and endorsed definitions for outcome measures for a range of common cardiovascular diseases and interventions are presented. These may be used for data alignment to enable high-quality observational and randomized clinical research, audit, and quality improvement for patient benefit.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545867</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae724>10.1093/eurheartj/ehae724</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545867</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Chris Wilkinson</dc:creator>
<dc:creator>Asad Bhatty</dc:creator>
<dc:creator>Gorav Batra</dc:creator>
<dc:creator>Suleman Aktaa</dc:creator>
<dc:creator>Adam B Smith</dc:creator>
<dc:creator>Jeremy Dwight</dc:creator>
<dc:creator>Marcin Ruciński</dc:creator>
<dc:creator>Sam Chappell</dc:creator>
<dc:creator>Joakim Alfredsson</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Jorge Ferreira</dc:creator>
<dc:creator>Ingibjörg J Guðmundsdóttir</dc:creator>
<dc:creator>Þórdís Jóna Hrafnkelsdóttir</dc:creator>
<dc:creator>Inga Jóna Ingimarsdóttir</dc:creator>
<dc:creator>Alar Irs</dc:creator>
<dc:creator>András Jánosi</dc:creator>
<dc:creator>Zoltán Járai</dc:creator>
<dc:creator>Manuel Oliveira-Santos</dc:creator>
<dc:creator>Bogdan A Popescu</dc:creator>
<dc:creator>Peter Vasko</dc:creator>
<dc:creator>Dragos Vinereanu</dc:creator>
<dc:creator>Jonathan Yap</dc:creator>
<dc:creator>Raffaele Bugiardini</dc:creator>
<dc:creator>Edina Cenko</dc:creator>
<dc:creator>Ramesh Nadarajah</dc:creator>
<dc:creator>Matthew R Sydes</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Lars Wallentin</dc:creator>
<dc:creator>Barbara Casadei</dc:creator>
<dc:creator>Chris P Gale</dc:creator>
<dc:creator>Global Cardiovascular Outcomes Consortium and in collaboration with ACNAP, ACVC, EACVI, EAPC, EAPCI, EHRA, ESC Committee for Young CV Professionals, ESC Registry Committee, HFA, ESC Patient Forum and these Working Groups: aorta and peripheral vascular diseases, atherosclerosis and vascular biology, cardiac cellular electrophysiology, cardiovascular pharmacotherapy, cardiovascular regenerative and restorative medicine, cardiovascular surgery, cellular biology of the heart, e-cardiology, myocardial function, pulmonary circulation and right ventricular function and thrombosis</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)</dc:title>
<dc:identifier>pmid:39545867</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae724</dc:identifier>
</item>
<item>
<title>Fasting prior to percutaneous cardiovascular procedures: is it time to abandon this time-honoured practice?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 15:ehae754. doi: 10.1093/eurheartj/ehae754. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545812/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39545812</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae754>10.1093/eurheartj/ehae754</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545812</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Muhammad H Maqsood</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fasting prior to percutaneous cardiovascular procedures: is it time to abandon this time-honoured practice?</dc:title>
<dc:identifier>pmid:39545812</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae754</dc:identifier>
</item>
<item>
<title>Improving English proficiency for scientific communication by non-fluent speakers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39543309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 14. doi: 10.1038/s41569-024-01102-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39543309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39543309</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01102-1>10.1038/s41569-024-01102-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39543309</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dong Zhao</dc:creator>
<dc:creator>Maria Rubini</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Improving English proficiency for scientific communication by non-fluent speakers</dc:title>
<dc:identifier>pmid:39543309</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01102-1</dc:identifier>
</item>
<item>
<title>Trade-offs between vessel-based and substrate-based nomenclatures for coronary heart diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39543308/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 14. doi: 10.1038/s41569-024-01099-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39543308/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39543308</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01099-7>10.1038/s41569-024-01099-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39543308</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Robert A Byrne</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Trade-offs between vessel-based and substrate-based nomenclatures for coronary heart diseases</dc:title>
<dc:identifier>pmid:39543308</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01099-7</dc:identifier>
</item>
<item>
<title>Monocytes migrate to the brain after MI to promote deep sleep to aid cardiac healing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39543307/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 14. doi: 10.1038/s41569-024-01106-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39543307/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39543307</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01106-x>10.1038/s41569-024-01106-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39543307</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Monocytes migrate to the brain after MI to promote deep sleep to aid cardiac healing</dc:title>
<dc:identifier>pmid:39543307</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01106-x</dc:identifier>
</item>
<item>
<title>Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39541968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>The microbiota in individual habitats differ in both relative composition and absolute abundance. While sequencing approaches determine the relative abundances of taxa and genes, they do not provide information on their absolute abundances. Here, we developed a machine-learning approach to predict fecal microbial loads (microbial cells per gram) solely from relative abundance data. Applying our prediction model to a large-scale metagenomic dataset (n = 34,539), we demonstrated that microbial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 4:S0092-8674(24)01204-2. doi: 10.1016/j.cell.2024.10.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The microbiota in individual habitats differ in both relative composition and absolute abundance. While sequencing approaches determine the relative abundances of taxa and genes, they do not provide information on their absolute abundances. Here, we developed a machine-learning approach to predict fecal microbial loads (microbial cells per gram) solely from relative abundance data. Applying our prediction model to a large-scale metagenomic dataset (n = 34,539), we demonstrated that microbial load is the major determinant of gut microbiome variation and is associated with numerous host factors, including age, diet, and medication. We further found that for several diseases, changes in microbial load, rather than the disease condition itself, more strongly explained alterations in patients' gut microbiome. Adjusting for this effect substantially reduced the statistical significance of the majority of disease-associated species. Our analysis reveals that the fecal microbial load is a major confounder in microbiome studies, highlighting its importance for understanding microbiome variation in health and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39541968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39541968</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.022>10.1016/j.cell.2024.10.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39541968</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Suguru Nishijima</dc:creator>
<dc:creator>Evelina Stankevic</dc:creator>
<dc:creator>Oliver Aasmets</dc:creator>
<dc:creator>Thomas S B Schmidt</dc:creator>
<dc:creator>Naoyoshi Nagata</dc:creator>
<dc:creator>Marisa Isabell Keller</dc:creator>
<dc:creator>Pamela Ferretti</dc:creator>
<dc:creator>Helene Bæk Juel</dc:creator>
<dc:creator>Anthony Fullam</dc:creator>
<dc:creator>Shahriyar Mahdi Robbani</dc:creator>
<dc:creator>Christian Schudoma</dc:creator>
<dc:creator>Johanne Kragh Hansen</dc:creator>
<dc:creator>Louise Aas Holm</dc:creator>
<dc:creator>Mads Israelsen</dc:creator>
<dc:creator>Robert Schierwagen</dc:creator>
<dc:creator>Nikolaj Torp</dc:creator>
<dc:creator>Anja Telzerow</dc:creator>
<dc:creator>Rajna Hercog</dc:creator>
<dc:creator>Stefanie Kandels</dc:creator>
<dc:creator>Diënty H M Hazenbrink</dc:creator>
<dc:creator>Manimozhiyan Arumugam</dc:creator>
<dc:creator>Flemming Bendtsen</dc:creator>
<dc:creator>Charlotte Brøns</dc:creator>
<dc:creator>Cilius Esmann Fonvig</dc:creator>
<dc:creator>Jens-Christian Holm</dc:creator>
<dc:creator>Trine Nielsen</dc:creator>
<dc:creator>Julie Steen Pedersen</dc:creator>
<dc:creator>Maja Sofie Thiele</dc:creator>
<dc:creator>Jonel Trebicka</dc:creator>
<dc:creator>Elin Org</dc:creator>
<dc:creator>Aleksander Krag</dc:creator>
<dc:creator>Torben Hansen</dc:creator>
<dc:creator>Michael Kuhn</dc:creator>
<dc:creator>Peer Bork</dc:creator>
<dc:creator>GALAXY and MicrobLiver Consortia</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations</dc:title>
<dc:identifier>pmid:39541968</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.022</dc:identifier>
</item>
<item>
<title>Coronary air embolism causing myocardial infarction following a blunt chest trauma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39540942/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 14:ehae771. doi: 10.1093/eurheartj/ehae771. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39540942/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39540942</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae771>10.1093/eurheartj/ehae771</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39540942</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Elise Bendriss</dc:creator>
<dc:creator>Jean Pasqueron</dc:creator>
<dc:creator>Jean Bardon</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary air embolism causing myocardial infarction following a blunt chest trauma</dc:title>
<dc:identifier>pmid:39540942</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae771</dc:identifier>
</item>
<item>
<title>A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39540306/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Measurement of targeted protein biomarkers produced superior prediction of aggregated and disaggregated cardiovascular events. This study represents an important proof of concept for the application of targeted proteomics in predicting a range of cardiovascular outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 14. doi: 10.1161/CIRCULATIONAHA.124.070454. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. We sought to investigate the use of a plasma proteomics-based approach in predicting different cardiovascular outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 51 859 UK Biobank participants (mean age, 56.7 years; 45.5% male) without cardiovascular disease and with proteomics measurements, we examined the primary composite outcome of fatal and nonfatal coronary heart disease, stroke, or heart failure (major adverse cardiovascular events), as well as additional secondary cardiovascular outcomes. An exposome-wide association study was conducted using relative protein concentrations, adjusted for a range of classic, demographic, and lifestyle risk factors. A prediction model using only age, sex, and protein markers (protein model) was developed using a least absolute shrinkage and selection operator-regularized approach (derivation: 80% of cohort) and validated using split-sample testing (20% of cohort). Their performance was assessed by comparing calibration, net reclassification index, and <i>c</i> statistic with the PREVENT (Predicting Risk of CVD Events) risk score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median 13.6 years of follow-up, 4857 participants experienced first major adverse cardiovascular events. After adjustment, the proteins most strongly associated with major adverse cardiovascular events included NT-proBNP (N-terminal pro B-type natriuretic peptide; hazard ratio [HR], 1.68 per SD increase), proADM (pro-adrenomedullin; HR, 1.60), GDF-15 (growth differentiation factor-15; HR, 1.47), WFDC2 (WAP four-disulfide core domain protein 2; HR, 1.46), and IGFBP4 (insulin-like growth factor-binding protein 4; HR, 1.41). In total, 222 separate proteins were predictors of all outcomes of interest in the protein model, and 86 were selected for the primary outcome specifically. In the validation cohort, compared with the PREVENT risk factor model, the protein model improved calibration, net reclassification (net reclassification index +0.09), and <i>c</i> statistic for major adverse cardiovascular events (+0.051). The protein model also improved the prediction of other outcomes, including ASCVD (<i>c</i> statistic +0.035), myocardial infarction (+0.023), stroke (+0.024), aortic stenosis (+0.015), heart failure (+0.060), abdominal aortic aneurysm (+0.024), and dementia (+0.068).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Measurement of targeted protein biomarkers produced superior prediction of aggregated and disaggregated cardiovascular events. This study represents an important proof of concept for the application of targeted proteomics in predicting a range of cardiovascular outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39540306/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39540306</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070454>10.1161/CIRCULATIONAHA.124.070454</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39540306</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Frederick K Ho</dc:creator>
<dc:creator>Patrick B Mark</dc:creator>
<dc:creator>Jennifer S Lees</dc:creator>
<dc:creator>Jill P Pell</dc:creator>
<dc:creator>Rona J Strawbridge</dc:creator>
<dc:creator>Dorien M Kimenai</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Mark Woodward</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Naveed Sattar</dc:creator>
<dc:creator>Paul Welsh</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia</dc:title>
<dc:identifier>pmid:39540306</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070454</dc:identifier>
</item>
<item>
<title>2024 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39540293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>This is the eighth annual summary of the International Liaison Committee on Resuscitation International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations; a more comprehensive review was done in 2020. This latest summary addresses the most recent published resuscitation evidence reviewed by the International Liaison Committee on Resuscitation task force science experts. Members from 6 International Liaison Committee on...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 14. doi: 10.1161/CIR.0000000000001288. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This is the eighth annual summary of the International Liaison Committee on Resuscitation International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations; a more comprehensive review was done in 2020. This latest summary addresses the most recent published resuscitation evidence reviewed by the International Liaison Committee on Resuscitation task force science experts. Members from 6 International Liaison Committee on Resuscitation task forces have assessed, discussed, and debated the quality of the evidence, using Grading of Recommendations Assessment, Development, and Evaluation criteria, and their statements include consensus treatment recommendations. Insights into the deliberations of the task forces are provided in the Justification and Evidence-to-Decision Framework Highlights sections. In addition, the task forces list priority knowledge gaps for further research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39540293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39540293</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001288>10.1161/CIR.0000000000001288</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39540293</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Robert Greif</dc:creator>
<dc:creator>Janet E Bray</dc:creator>
<dc:creator>Therese Djärv</dc:creator>
<dc:creator>Ian R Drennan</dc:creator>
<dc:creator>Helen G Liley</dc:creator>
<dc:creator>Kee-Chong Ng</dc:creator>
<dc:creator>Adam Cheng</dc:creator>
<dc:creator>Matthew J Douma</dc:creator>
<dc:creator>Barnaby R Scholefield</dc:creator>
<dc:creator>Michael Smyth</dc:creator>
<dc:creator>Gary Weiner</dc:creator>
<dc:creator>Cristian Abelairas-Gómez</dc:creator>
<dc:creator>Jason Acworth</dc:creator>
<dc:creator>Natalie Anderson</dc:creator>
<dc:creator>Dianne L Atkins</dc:creator>
<dc:creator>David C Berry</dc:creator>
<dc:creator>Farhan Bhanji</dc:creator>
<dc:creator>Bernd W Böttiger</dc:creator>
<dc:creator>Richard N Bradley</dc:creator>
<dc:creator>Jan Breckwoldt</dc:creator>
<dc:creator>Jestin N Carlson</dc:creator>
<dc:creator>Pascal Cassan</dc:creator>
<dc:creator>Wei-Tien Chang</dc:creator>
<dc:creator>Nathan P Charlton</dc:creator>
<dc:creator>Sung Phil Chung</dc:creator>
<dc:creator>Julie Considine</dc:creator>
<dc:creator>Andrea Cortegiani</dc:creator>
<dc:creator>Daniela T Costa-Nobre</dc:creator>
<dc:creator>Keith Couper</dc:creator>
<dc:creator>Thomaz Bittencourt Couto</dc:creator>
<dc:creator>Katie N Dainty</dc:creator>
<dc:creator>Vihara Dassanayake</dc:creator>
<dc:creator>Peter G Davis</dc:creator>
<dc:creator>Jennifer A Dawson</dc:creator>
<dc:creator>Allan R de Caen</dc:creator>
<dc:creator>Charles D Deakin</dc:creator>
<dc:creator>Guillaume Debaty</dc:creator>
<dc:creator>Jimena Del Castillo</dc:creator>
<dc:creator>Maya Dewan</dc:creator>
<dc:creator>Bridget Dicker</dc:creator>
<dc:creator>Jana Djakow</dc:creator>
<dc:creator>Aaron J Donoghue</dc:creator>
<dc:creator>Kathryn Eastwood</dc:creator>
<dc:creator>Walid El-Naggar</dc:creator>
<dc:creator>Raffo Escalante-Kanashiro</dc:creator>
<dc:creator>Jorge Fabres</dc:creator>
<dc:creator>Barbara Farquharson</dc:creator>
<dc:creator>Joe Fawke</dc:creator>
<dc:creator>Maria Fernanda de Almeida</dc:creator>
<dc:creator>Shannon M Fernando</dc:creator>
<dc:creator>Emer Finan</dc:creator>
<dc:creator>Judith Finn</dc:creator>
<dc:creator>Gustavo E Flores</dc:creator>
<dc:creator>Elizabeth E Foglia</dc:creator>
<dc:creator>Fredrik Folke</dc:creator>
<dc:creator>Craig A Goolsby</dc:creator>
<dc:creator>Asger Granfeldt</dc:creator>
<dc:creator>Anne-Marie Guerguerian</dc:creator>
<dc:creator>Ruth Guinsburg</dc:creator>
<dc:creator>Carolina Malta Hansen</dc:creator>
<dc:creator>Tetsuo Hatanaka</dc:creator>
<dc:creator>Karen G Hirsch</dc:creator>
<dc:creator>Mathias J Holmberg</dc:creator>
<dc:creator>Stuart Hooper</dc:creator>
<dc:creator>Amber V Hoover</dc:creator>
<dc:creator>Ming-Ju Hsieh</dc:creator>
<dc:creator>Takanari Ikeyama</dc:creator>
<dc:creator>Tetsuya Isayama</dc:creator>
<dc:creator>Nicholas J Johnson</dc:creator>
<dc:creator>Justin Josephsen</dc:creator>
<dc:creator>Anup Katheria</dc:creator>
<dc:creator>Mandira D Kawakami</dc:creator>
<dc:creator>Monica Kleinman</dc:creator>
<dc:creator>David Kloeck</dc:creator>
<dc:creator>Ying-Chih Ko</dc:creator>
<dc:creator>Peter Kudenchuk</dc:creator>
<dc:creator>Amy Kule</dc:creator>
<dc:creator>Hiroshi Kurosawa</dc:creator>
<dc:creator>Jorien Laermans</dc:creator>
<dc:creator>Anthony Lagina</dc:creator>
<dc:creator>Kasper G Lauridsen</dc:creator>
<dc:creator>Eric J Lavonas</dc:creator>
<dc:creator>Henry C Lee</dc:creator>
<dc:creator>Swee Han Lim</dc:creator>
<dc:creator>Yiqun Lin</dc:creator>
<dc:creator>Andrew S Lockey</dc:creator>
<dc:creator>Jesus Lopez-Herce</dc:creator>
<dc:creator>George Lukas</dc:creator>
<dc:creator>Finlay Macneil</dc:creator>
<dc:creator>Ian K Maconochie</dc:creator>
<dc:creator>John Madar</dc:creator>
<dc:creator>Abel Martinez-Mejas</dc:creator>
<dc:creator>Siobhan Masterson</dc:creator>
<dc:creator>Tasuku Matsuyama</dc:creator>
<dc:creator>Richard Mausling</dc:creator>
<dc:creator>Christopher J D McKinlay</dc:creator>
<dc:creator>Daniel Meyran</dc:creator>
<dc:creator>William Montgomery</dc:creator>
<dc:creator>Peter T Morley</dc:creator>
<dc:creator>Laurie J Morrison</dc:creator>
<dc:creator>Ari L Moskowitz</dc:creator>
<dc:creator>Michelle Myburgh</dc:creator>
<dc:creator>Sabine Nabecker</dc:creator>
<dc:creator>Vinay Nadkarni</dc:creator>
<dc:creator>Firdose Nakwa</dc:creator>
<dc:creator>Kevin J Nation</dc:creator>
<dc:creator>Ziad Nehme</dc:creator>
<dc:creator>Tonia Nicholson</dc:creator>
<dc:creator>Nikolaos Nikolaou</dc:creator>
<dc:creator>Chika Nishiyama</dc:creator>
<dc:creator>Tatsuya Norii</dc:creator>
<dc:creator>Gabrielle Nuthall</dc:creator>
<dc:creator>Shinichiro Ohshimo</dc:creator>
<dc:creator>Theresa Olasveengen</dc:creator>
<dc:creator>Alexander Olaussen</dc:creator>
<dc:creator>Gene Ong</dc:creator>
<dc:creator>Aaron Orkin</dc:creator>
<dc:creator>Michael J Parr</dc:creator>
<dc:creator>Gavin D Perkins</dc:creator>
<dc:creator>Helen Pocock</dc:creator>
<dc:creator>Yacov Rabi</dc:creator>
<dc:creator>Violetta Raffay</dc:creator>
<dc:creator>James Raitt</dc:creator>
<dc:creator>Tia Raymond</dc:creator>
<dc:creator>Giuseppe Ristagno</dc:creator>
<dc:creator>Antonio Rodriguez-Nunez</dc:creator>
<dc:creator>Joseph Rossano</dc:creator>
<dc:creator>Mario Rüdiger</dc:creator>
<dc:creator>Claudio Sandroni</dc:creator>
<dc:creator>Taylor L Sawyer</dc:creator>
<dc:creator>Stephen M Schexnayder</dc:creator>
<dc:creator>Georg Schmölzer</dc:creator>
<dc:creator>Sebastian Schnaubelt</dc:creator>
<dc:creator>Anna Lene Seidler</dc:creator>
<dc:creator>Federico Semeraro</dc:creator>
<dc:creator>Eunice M Singletary</dc:creator>
<dc:creator>Markus B Skrifvars</dc:creator>
<dc:creator>Christopher M Smith</dc:creator>
<dc:creator>Jasmeet Soar</dc:creator>
<dc:creator>Anne Lee Solevåg</dc:creator>
<dc:creator>Roger Soll</dc:creator>
<dc:creator>Willem Stassen</dc:creator>
<dc:creator>Takahiro Sugiura</dc:creator>
<dc:creator>Kaushila Thilakasiri</dc:creator>
<dc:creator>Janice Tijssen</dc:creator>
<dc:creator>Lokesh Kumar Tiwari</dc:creator>
<dc:creator>Alexis Topjian</dc:creator>
<dc:creator>Daniele Trevisanuto</dc:creator>
<dc:creator>Christian Vaillancourt</dc:creator>
<dc:creator>Michelle Welsford</dc:creator>
<dc:creator>Myra H Wyckoff</dc:creator>
<dc:creator>Chih-Wei Yang</dc:creator>
<dc:creator>Joyce Yeung</dc:creator>
<dc:creator>Carolyn M Zelop</dc:creator>
<dc:creator>David A Zideman</dc:creator>
<dc:creator>Jerry P Nolan</dc:creator>
<dc:creator>Katherine M Berg</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2024 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</dc:title>
<dc:identifier>pmid:39540293</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001288</dc:identifier>
</item>
<item>
<title>2024 American Heart Association and American Red Cross Guidelines for First Aid</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39540278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>Codeveloped by the American Heart Association and the American Red Cross, these guidelines represent the first comprehensive update of first aid treatment recommendations since 2010. Incorporating the results of structured evidence reviews from the International Liaison Committee on Resuscitation, these guidelines cover first aid treatment for critical and common medical, traumatic, environmental, and toxicological conditions. This update emphasizes the continuous evolution of evidence...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 14. doi: 10.1161/CIR.0000000000001281. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Codeveloped by the American Heart Association and the American Red Cross, these guidelines represent the first comprehensive update of first aid treatment recommendations since 2010. Incorporating the results of structured evidence reviews from the International Liaison Committee on Resuscitation, these guidelines cover first aid treatment for critical and common medical, traumatic, environmental, and toxicological conditions. This update emphasizes the continuous evolution of evidence evaluation and the necessity of adapting educational strategies to local needs and diverse community demographics. Existing guidelines remain relevant unless specifically updated in this publication. Key topics that are new, are substantially revised, or have significant new literature include opioid overdose, bleeding control, open chest wounds, spinal motion restriction, hypothermia, frostbite, presyncope, anaphylaxis, snakebite, oxygen administration, and the use of pulse oximetry in first aid, with the inclusion of pediatric-specific guidance as warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39540278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39540278</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001281>10.1161/CIR.0000000000001281</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39540278</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Elizabeth K Hewett Brumberg</dc:creator>
<dc:creator>Matthew J Douma</dc:creator>
<dc:creator>Kostas Alibertis</dc:creator>
<dc:creator>Nathan P Charlton</dc:creator>
<dc:creator>Michael P Goldman</dc:creator>
<dc:creator>Katrina Harper-Kirksey</dc:creator>
<dc:creator>Seth C Hawkins</dc:creator>
<dc:creator>Amber V Hoover</dc:creator>
<dc:creator>Amy Kule</dc:creator>
<dc:creator>Stefan Leichtle</dc:creator>
<dc:creator>Sarah Frances McClure</dc:creator>
<dc:creator>George Sam Wang</dc:creator>
<dc:creator>Mark Whelchel</dc:creator>
<dc:creator>Lynn White</dc:creator>
<dc:creator>Eric J Lavonas</dc:creator>
<dc:creator>American Heart Association and American Red Cross</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2024 American Heart Association and American Red Cross Guidelines for First Aid</dc:title>
<dc:identifier>pmid:39540278</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001281</dc:identifier>
</item>
<item>
<title>Unipolar Voltage Mapping to Predict Recovery of Left Ventricular Ejection Fraction in Patients With Recent-Onset Nonischemic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39540275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116011409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Left ventricular unipolar voltage abnormality is a potent predictor of LVEF recovery among patients recently diagnosed with nonischemic cardiomyopathy. Detailed left ventricular unipolar voltage mapping could therefore be used as a valuable prognostic tool in guiding treatment decisions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 14. doi: 10.1161/CIRCULATIONAHA.124.070501. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought to determine whether left ventricular endocardial unipolar voltage measured during invasive electroanatomic mapping could be used to predict LVEF recovery among those with recent-onset nonischemic cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We analyzed the left ventricular voltage maps of patients included in the eMAP trial (Electrogram-Guided Myocardial Advanced Phenotyping; NCT03293381), a prospective, nonrandomized, interventional trial conducted at 2 institutions between 2017 and 2020. Patients had recent-onset nonischemic cardiomyopathy defined by LVEF ≤45% and development of symptoms or signs of heart failure within the past 6 months. Detailed voltage maps of the left ventricular endocardium were generated using the CARTO electroanatomic mapping system. Abnormal unipolar amplitude was defined as &lt;8.27 mV. The primary end point was recovery of LVEF (Recovery) defined by a 1-year LVEF ≥50% or ≥45% with ≥10% increase from baseline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 29 enrolled patients (median age, 49 years [25th percentile, 39; 75th percentile, 59], 8 females [27.6%]), LVEF recovered in 13 (44.8%) by 1-year follow-up. The percentage of total endocardial surface area with unipolar voltage abnormality (AUA) was significantly lower among Recovery patients than No Recovery patients (18.2% [6.4, 22.4] versus 80.0% [29.5, 90.9]; <i>P</i>=0.004). Percent AUA was associated with lower likelihood of Recovery (odds ratio, 0.64 per 10% increase in AUA; 95% CI, 0.47-0.88; <i>P</i>=0.006). A 28% cutoff value for percent AUA was 92% sensitive and 75% specific with an area under the receiver operating characteristic curve of 0.81 (95% CI, 0.63-0.99; <i>P</i>=0.001) for predicting recovery versus no recovery. The majority of patients (12 of 13; 92.3%) with a percent AUA >;28% did not recover.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Left ventricular unipolar voltage abnormality is a potent predictor of LVEF recovery among patients recently diagnosed with nonischemic cardiomyopathy. Detailed left ventricular unipolar voltage mapping could therefore be used as a valuable prognostic tool in guiding treatment decisions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39540275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116011409&v=2.18.0.post9+e462414">39540275</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070501>10.1161/CIRCULATIONAHA.124.070501</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39540275</guid>
<pubDate>Thu, 14 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Corentin Chaumont</dc:creator>
<dc:creator>Eliot Peyster</dc:creator>
<dc:creator>Konstantinos C Siontis</dc:creator>
<dc:creator>Daniele Muser</dc:creator>
<dc:creator>Suraj Kapa</dc:creator>
<dc:creator>Timothy M Markman</dc:creator>
<dc:creator>Rajeev K Pathak</dc:creator>
<dc:creator>Alireza Oraii</dc:creator>
<dc:creator>Oriol Rodriguez-Queralto</dc:creator>
<dc:creator>Frederic Anselme</dc:creator>
<dc:creator>Kenneth B Margulies</dc:creator>
<dc:creator>Francis E Marchlinski</dc:creator>
<dc:creator>David S Frankel</dc:creator>
<dc:date>2024-11-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unipolar Voltage Mapping to Predict Recovery of Left Ventricular Ejection Fraction in Patients With Recent-Onset Nonischemic Cardiomyopathy</dc:title>
<dc:identifier>pmid:39540275</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070501</dc:identifier>
</item>





























</channel>
</rss>